Gynecologic Cancer,Ovarian Cancer Pros in the Mirasol and Forward I Trial on the Effect of MIRV in the Treatment of PROC Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer Olaparib vs. Non-Platinum Chemotherapy for PSROC with BRCA1/2 Mutations Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer Maintenance Olaparib in PSROC: Safety and Efficacy Regardless of BRCA Status Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer Viability of Rucaparib for Recurring Ovarian Cancer: A Study Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer 7-Year Follow-Up: Olaparib as First-Line for Advanced Ovarian Cancer Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer Efficacy of First-Line Rucaparib Maintenance for Ovarian Cancer by Disease Risk Subgroups Mar 28, 2023
Cervical Cancer,Gynecologic Cancer Durvalumab Compared To SoC CCRT In Treating Women With LACC Mar 28, 2023
Gynecologic Cancer,Ovarian Cancer BOOST Phase III Trial: Optimal Duration of Bevacizumab for Ovarian Cancer Mar 27, 2023
